Methods. A case-case study examining heterogeneity of risk factors between disease subgroups compared personal characteristics and EBV antibodies between 95 EBV-positive and 303 EBV-negative patients with HL.
Hodgkin lymphoma (HL) has long been postulated to have an infectious etiology. The evidence that supports this theory includes clinical symptoms, such as persistent fever, night sweats, weight loss, and lymphadenopathy [1] ; the abundance of reactive lymphocytes surrounding the sparse malignant Hodgkin and Reed-Sternberg (HRS) cells of HL tumors [2, 3] ; the unusual bimodal age-incidence curve [4] ; and previous epidemiological findings that factors related to delayed childhood infection are predictive of HL in young and middle-aged adults [5, 6] .
Monoclonal Epstein-Barr virus (EBV) DNA and its gene products can be detected in 25%-50% of HL biopsy samples, in which the virus is localized to the HRS cells [2, 3] . EBV is a ubiquitous human herpesvirus that infects 190% of the worldwide population, usually during childhood, and typically persists latently for life [7] . When primary infection is postponed until adolescence, EBV can cause infectious mononucleosis (IM) in up to half of patients [8, 9] . IM, in turn, is associated with a 3-fold greater risk of subsequent HL [6, [10] [11] [12] [13] [14] [15] [16] . Additional evidence that links EBV to HL includes altered antibody titers to EBV antigens, which suggests viral reactivation and enhanced replication, preceding a diagnosis of HL [17] [18] [19] . These findings, and the fact that EBV has well-characterized oncogenic properties in vivo, implicate EBV as the major suspect in HL etiology [20] . Although EBV carriers produce antibodies to a variety of lytic and latent EBV antigens, these antibodies appear to offer little or no control over the virus in latently infected cells; rather, immune control is mediated primarily by cytotoxic T lymphocytes (CTLs) [21, 22] . However, the level and prevalence of antibodies to lytic and latent viral proteins appear to reflect the prevalence of these proteins expressed in the carrier and, as such, can indirectly gauge the host response to EBV infection. In normal hosts, primary EBV infection triggers the production of antibodies against the viral capsid antigen (VCA) and early antigen (EA), which signifies viral replication, as well as the latent Epstein-Barr nuclear protein (EBNA)-2. Elevated IgG antibody titers against VCA may suggest a relatively severe primary infection or reactivated EBV [23] , whereas elevated antibodies against EA are believed to reflect active viral replication and a less efficient host immune response [22, 23] . The resolution of early infection is reflected in the appearance of anti-EBNA-1 and the decline of anti-EBNA-2, which results in an anti-EBNA-1:anti-EBNA-2 ratio 11.0 in normal carriers [22] . A persistent anti-EBNA-1:anti-EBNA-2 ratio р1.0 is empirically interpreted as a marker of defective host immune control of latent EBV infection [24, 25] and has been detected in patients with HL (N.E.M., E. T.L., K. Dupnik, and B. Birmann unpublished data) and in patients with severe IM, chronic EBV infection, AIDS, and congenital immune deficiency [24] .
Because evidence of the EBV genome exists in only a proportion of HL tumors, the question arises of whether EBVpositive and -negative patients share the same etiology. Previous studies have found that EBV-positive HL appears to be more common in males, children and older adults, nonwhite persons, economically less-developed regions, and persons with the mixed-cellularity (MC) histological subtype of HL [15, [26] [27] [28] [29] [30] [31] [32] [33] . Few previous studies have interviewed patients to identify additional risk factors for EBV genome positivity among patients with HL [15, 32, 34] . Two small studies [35, 36] evaluated EBV serology and the presence of its genome in HL tumors and found no correlation. We conducted a case-case comparison that evaluated personal, histological, and serological differences between patients with EBV-positive and EBV-negative HL.
SUBJECTS AND METHODS

Study population.
In 1997 we initiated a population-based case-control study that included the combined populations of the greater Boston, Massachusetts, metropolitan area and the state of Connecticut, to clarify the role of EBV in the etiology of HL. The patients included in the present study were diagnosed at age 15-79 years, lived in the defined area, and had no reported evidence of HIV infection. Within the study area, 743 eligible patients with HL were diagnosed between 1 August 1997 and 31 December 2001. Permission for contacting patients was sought from the treating physician for each identified patient and was granted for 685 (92%) of 743 patients. Each patient was then sent an initial explanatory letter inviting their participation in the study. Of the eligible patients contacted for interview by study staff, 335 (84%) of 398 patients in Massachusetts and 240 (86%) of 280 patients in Connecticut participated. Ten patients were excluded by study pathologists for not having HL, leaving a total of 565 patients with HL for the study. This research protocol was approved by the institutional review boards and ethics committees of the Harvard School of Public Health, the Yale University School of Medicine, and the Johns Hopkins Medical School. We assume full responsibility for analyses and interpretation of these data. All study participants or, if they were minors, their guardians gave written informed consent at the time of enrollment in the study.
Data collection. The explanatory letter was followed by a telephone request for scheduling a structured telephone interview. Next-of-kin interviews were performed for 2 patients, and 1 patient who did not wish to perform a telephone interview completed an abbreviated, mailed questionnaire. The interviews gathered information on several exposures, including personal demographic characteristics, occupation, childhood social environment at age ∼8 years, family structure, parental education and occupation, tobacco use, and personal and family medical history. Data on median household income in census tract and percentage of census tract below poverty level, according to the United States Census, were obtained on the basis of each patient's residential street address [37] .
Histopathologic testing.
The study pathologists (M.B., R.B.M., and E.G.W.) reviewed all available pathologic material to verify the diagnosis of HL. Archived tissue blocks were retrieved and examined for 411 (71%) of 575 patients. For those patients without adequate, available, or consented diagnostic specimens, the original pathology reports were reviewed to determine whether a diagnosis of HL was probable, possible, unlikely, or unconfirmable. Pathology report-based diagnoses were made for 156 patients (27%), and pathological material was unavailable for 8 (1%). The histopathologic classification of tumors was based on the 1994 Revised European-American Lymphoma Classification of Lymphoid Neoplasms and the 2001 World Health Organization Classification of Hematopoietic and Lymphoid Tumors [38, 39] . These classifications distinguish among several subtypes considered broadly as "classic" HL: nodular sclerosis (NS), MC, lymphocyte depletion, and lymphocyte-rich classic HL. Nodular lymphocyte predominance (NLP) HL is considered to be a disease entity that is distinct from the classic subtypes and was excluded from the present analysis. Study pathologists also confirmed cases of classic HL that could not be further subclassified, including those for which there was an insufficient amount of diagnostic tissue for subtyping, as well as those in which NS and MC HL could not be differentiated, because of early involvement of a lymph node in an interfollicular variant (IFV) pattern. The presence of EBV in HL tissue was determined by in situ hybridization for EBV-encoded RNA transcripts and/or immunohistochemical as-say for the viral latency membrane protein-1 in HRS cells [40, 41] . An HL tumor was considered to be EBV positive if results were positive for either assay; a tumor was considered to be EBV negative if both assays were negative or if only a single assay was performed and its result was negative [42] .
Where possible, tumor immunophenotypes were classified as typical, B cell-like, or T cell-like on the basis of immunoperoxidase reactivity patterns with cell-surface markers. Typical HRS cells were defined as those lacking both B and T cell markers; B cell-like cells were positive for CD20 and/or CD79a, and T cell-like cells were positive for CD3 and/or CD45RO. The interpretation of immunohistochemical assays was done by consensus of all 3 study pathologists.
Serology. Postdiagnosis blood samples were collected by clinical or study staff, from 469 (82%) of 575 initial patients. Serum samples were promptly processed and stored at Ϫ20ЊC before blinded testing at Virolab. The specific antibodies measured were IgG to EBV VCA, EA-restricted (EA-R), EA-diffuse (EA-D), EBNA complex, EBNA-1, and EBNA-2 and IgA to VCA and EA-D. If a patient had detectable anti-EA-R and anti-EA-D IgG, the higher value was taken to be the titer against EA, as in other studies [7] . Nonspecific IgG was measured against the EBV-negative B lymphoblastoid cell line BJAB; the 7 patients who had a ratio of titers to EBNA complex versus BJAB of !4.0 were excluded as having nonspecific antibodies. Methods for these assays have been described elsewhere [25] . Titers were expressed as the reciprocal of the highest dilution to register a positive reaction. Detectable titers were defined as either 1:20 anti-VCA IgA or IgG and anti-BJAB IgG and 1:5 for the other antibodies.
In accordance with the results of our previous studies [18, 43] , EBV antibody titers were dichotomized at the upper 15% (or nearest cutoff) of the distribution among all patients combined. On the basis of these criteria, elevated titers were defined as у1:2560 anti-VCA IgG, у1:20 anti-VCA IgA, у1:160 anti-EA IgG, у1:5 anti-EA-D IgA, у1:1280 anti-EBNA complex, у1:1280 anti-EBNA-1, and у1:160 anti-EBNA-2. An abnormal proportion of antibody titers against anti-EBNA-1 and anti-EBNA-2 was defined as a ratio р1.0.
Statistical methods. The case-series design was used to perform a case-case comparison of the relative risk for developing EBV-positive HL with the relative risk for developing EBV-negative HL [44, 45] . Odds ratios (ORs), 95% confidence intervals (CIs), and corresponding P values for x 2 tests of association were computed using multiple logistic regression.
All exposures with 12 levels were analyzed first as categorical variables and then as ordinal variables. Likelihood-ratio tests were performed to determine whether these exposures should be entered into statistical models as single ordinal terms. Where monotonic trends were observed for association with the log odds of EBV-positive versus EBV-negative HL, exposures were coded as ordinal variables in statistical models. After evaluating its linearity of association with EBV-positive HL, age was modeled as a continuous variable, except where noted. Potential confounders were considered on the basis of change-in-estimate criteria [46] and likelihood-ratio tests that compared models with and without additional variables.
To detect the modification of associations with EBV-positive HL, the data were stratified by additional factors to examine differences in the OR across patient subgroups. The presence of effect modification was assessed by use of likelihood-ratio tests for the significance of interaction terms in multivariate models. Group means were compared by 2-sample t tests that assumed unequal group variances [47] , and locations of antibody distributions were compared by use of Wilcoxon rank-sum tests, all with 2-sided P values. Statistical analyses were performed with SAS System software (version 8.01; SAS Institute).
RESULTS
Tissue specimens were available for histopathologic confirmation from 402 patients with HL. Combined with 8 additional patients who lacked tumor specimens but whose pathology reports contained information on previous molecular tests for EBV and excluding 9 patients with NLP HL, there were 401 patients for whom data on EBV histopathology were available. Of these, 95 (24%) tested positive for the presence of the EBV genome in tumor cells, 303 (76%) tested negative for the EBV genome, and 3 (1%) had inconclusive test results.
The distribution of demographic characteristics among the 95 EBV-positive and 303 EBV-negative patients is shown in table 1. Table 2 summarizes the associations of risk factors with EBV genome positivity, adjusting for age and sex only or for age, sex, education level, and smoking status. In these analyses, EBV-negative patients served as the referent group. As expected, EBV-positive patients were more than twice as likely as EBVnegative patients to be older (adjusted OR, 2.5; 95% CI, 1.3-4.5), when patients aged 55-79 years were compared with those aged 15-54 years. EBV-positive patients were also more likely than EBV-negative patients to be of MC (OR, 4.5; 95% CI, 2.3-8.7) or IFV (OR, 3.2; 95% CI, 1.0-9.9) histological type, and there was a somewhat higher proportion of male patients (OR, 1.6; 95% CI, 1.0-2.6; table 2). No significant variation in risk of EBV-positive HL by race was found, although there was a low proportion of nonwhite patients in our study. EBV genome status did not appear to be associated with tumor immunophenotype.
Previous case-control studies have found an association between overall HL and markers of high socioeconomic status (SES) during childhood. In our case-case analyses, we found that these factors did not differ significantly between EBVpositive and EBV-negative patients, although the fathers of EBV-positive patients had somewhat lower levels of education than those of EBV-negative patients (table 2) . On average, EBVpositive patients were also less educated than EBV-negative patients (OR, 0.8; 95% CI, 0.6-1.0). The effect of several other risk factors for HL did not differ between EBV-positive and EBV-negative patients. Although a self-reported history of IM and a family history of hematopoietic cancer are established risk factors for HL overall [48] , those researchers did not distinguish between EBV-positive and EBV-negative HL, as we did. Jewish ethnicity and previous employment in wood-processing industries, which have also been previously identified as risk factors for HL [1, 6, [48] [49] [50] , were not associated with EBV genome positivity in our results.
A history of cigarette smoking was more common among patients with EBV-positive HL: the OR for having smoked у10 packs of cigarettes during one's lifetime for EBV-positive versus EBV-negative patients was 1.8 (95% CI, 1.1-3.0). The positive association between smoking and EBV-positive HL was consistent across strata of age, sex, and other demographic factors, including SES.
Evidence of previous EBV infection, as indicated by detectable IgG antibody to VCA, was present in 424 (94%) of 449 patients with serological results for EBV. EBV-seronegative patients were significantly younger than seropositive patients, with a mean age of 30 years versus 40 years ( ). All 25 EBV-seronegative P p .004 patients had either EBV-negative tumors ( ) or tumors n p 18 without available EBV genome results. There were no significant associations between prior EBV infection and tumor histology, sex, race, or any characteristic other than age.
There were 370 patients in our study with both tumor EBV genome status and serological results; of these, 88 (24%) had EBV-positive HL and 282 (76%) had EBV-negative HL. The differences between EBV-positive and EBV-negative patients in prevalence of detectable antibody and in median antibody titer are presented in table 3. EBV-positive patients were more likely than EBV-negative patients to have detectable IgA antibody against VCA (OR, 4.4; 95% CI, 1.9-10), EA-D (OR, 21; 95% CI, 2.3-190), and anti-EA (OR, 2.5; 95% CI, 1.1-5.7) IgG, when we adjusted for age, sex, education level, and smoking status. All EBV-positive patients, but not all EBV-negative patients, had detectable IgG titers to VCA and EBNA complex (P p for both, Fisher's exact test). The titers of all antibodies .01 except anti-EBNA complex and anti-EBNA-1 were more highly distributed among EBV-positive than EBV-negative patients, whereas the median anti-EBNA-1:anti-EBNA-2 ratio was lower for EBV-positive patients ( for all comparisons). P р .02 We examined whether the prevalence of elevated antibody titer was associated with the risk of EBV-positive, compared with EBV-negative, HL (table 4) . EBV-positive HL samples were significantly more likely to have elevated titers against VCA (IgG and IgA) and EA-D, as well as an abnormal anti-EBNA-1:anti-EBNA-2 ratio. After mutually controlling for antibodies to VCA, EA-D, and the anti-EBNA-1:anti-EBNA-2 ratio, the associations with an anti-VCA IgG and anti-EBNA-1:anti-EBNA-2 ratio р1.0 remained statistically significant. The OR for anti-VCA IgG was 3.6 (95% CI, 1.4-8.7), and that for an anti-EBNA ratio р1.0 was 3.2 (95% CI, 1.1-9.0), with 25% of EBV-positive and 11% of EBV-negative patients having an anti-EBNA ratio р1.0.
Stratification by age, sex, and histological subtype of HL revealed that the particular antibodies predictive of EBV-positive HL-that is, elevated anti-VCA IgG and an abnormal anti-EBNA-1:anti-EBNA-2 ratio-generally did not differ between subgroups. The only statistically significant interaction was between age group and elevated anti-VCA IgG, with a higher OR among older patients ( for heterogeneity by P p .02 age). The adjusted OR for elevated anti-VCA IgG was 2.4 (95% CI, 1.3-4.7) among patients aged 15-54 years, whereas it was 17 (95% CI, 3.7-77) among patients aged 55-79 years. There was no heterogeneity of association by sex or tumor histology.
We combined our survey and serological data, mutually adjusting for all factors independently associated with risk of EBVpositive HL (table 5). After controlling for age, sex, education level, smoking status, tumor histology, elevated anti-VCA IgG, and an anti-EBNA-1:anti-EBNA-2 ratio р1.0, we found that histological type, elevated anti-VCA IgG, and lower education level had the strongest associations with EBV-positive HL. The OR for the MC versus the NS histological type was 3.2 (95% CI, 1.4-7.2), whereas that for elevated anti-VCA IgG was 3.1 (95% CI, 1.6-6.0), and that for patient education level was 0.7 (95% CI, 0.5-1.0). Cigarette smoking and an abnormal anti-EBNA-1:anti-EBNA-2 ratio also remained marginally associated with EBV-positive HL. The OR for smoking was 1.6 (95% CI, 0.8-3.1), and that for an anti-EBNA-1:anti-EBNA-2 ratio р1.0 was 1.9 (95% CI, 0.9-4.0). 
DISCUSSION
Our findings that patients with EBV-positive HL are more often older, male, of a lower SES, and with MC histological type are consistent with those of studies that were based on a variety of other populations worldwide [33] . Together, these findings suggest that EBV genome positivity in HL tumors may be correlated with a relative impairment of immune competence. Host immunity is known to decline with increasing age and poverty [52] [53] [54] . In addition, male patients have diminished cellular immunity relative to female patients [55] . Immune compromise could contribute to defective immunological surveillance and control of EBV infection, leading to viral reactivation, higher antibody titers against EBV, and, potentially, a higher risk of B cell transformation and the development of HL [56] . Past findings of racial or ethnic differences in EBV genome positivity may reflect disparities in SES or could represent a true variation in genetic susceptibility that is possibly linked to HLA type [57] . The somewhat low proportion of EBV-positive patients (24%) in our study, compared with others that have reported prevalences у30% in Western populations, could be attributable to our relatively young, predominantly white, and generally high-SES population, as well as to chance.
Besides confirming previous associations with EBV genome positivity, we found that cigarette smoking was more common among EBV-positive than EBV-negative patients. A recent casecontrol study reported a significantly increased risk of MC HL among current smokers [58] , a finding that may corroborate our results, because the prevalence of EBV positivity was higher among MC tumors. Smoking is known to impair both antibody-and cell-mediated immunity [59, 60] , which could, in turn, enhance the reactivation of EBV and contribute to the development of EBV-positive HL. In addition, Briggs et al. [58] proposed that the effects of cigarette smoking and EBV infection may interact in causing HL, on the basis of evidence that both smoking and EBV inhibit CD95/Fas-mediated apoptosis [61, 62] . HRS cells express the CD95/Fas receptor [63] , which presents a possible means for cigarette smoke and EBV to promote HRS cell survival by preventing apoptotic death.
Several risk factors for HL overall appeared to apply equally to EBV-positive and EBV-negative HL. Specifically, Jewish ethnic background, history of IM, family history of hematopoietic cancer, and occupational exposure to wood products were not differentially associated with EBV-positive HL. These findings suggest that the etiologies of EBV-positive and EBV-negative HL share at least some features in common, because some factors increased or decreased the risk for HL overall, regardless of EBV genome status. Our finding of no association between IM and EBV-positive HL contrasts with the results of a recent study by Hjalgrim et al. [51] , who reported a case-case OR of 2.7 (95% CI, 1.2-6.0) when they compared a history of IM between EBV-positive and EBV-negative patients with HL. The same study found a significant association between IM and EBV-positive patients versus control patients but not EBV-negative patients versus control patients ( for heteroge-P p .015 neity). A similar outcome was reported by Alexander et al. [34] , who detected a significantly elevated OR for history of IM in EBV-positive young-adult patients with HL but not EBV-negative patients, compared with control patients. However, their case-case OR for patients with HL who were aged 16-34 years was 1.76 (95% CI, 0.63-4.88); this estimate does not differ appreciably from our OR of 1.7 (95% CI, 0.6-4.5) for the same age group. The nonsignificant association between IM and EBV-positive HL in our study also corresponds with the results of Sleckman et al. [32] , who found an OR that was elevated but not statistically significant.
Our serological results show that host antibody response to EBV varies significantly between EBV-positive and EBV-negative patients with HL. EBV-positive patients were more likely to be EBV carriers; in fact, none of the EBV-seronegative patients had EBV-positive tumors. In addition, EBV-positive patients were more likely than EBV-negative patients to have both detectable and elevated EBV antibody titers. The antibody titers that differentiated between EBV-positive and EBV-negative samples were directed against both lytic and latent virus antigens, which suggests an aberrant immune response to the virus in both of its states. A depressed ratio of titers to EBNA-1 and EBNA-2, which has previously been found to be a sensitive marker of defective immunity against EBV [24, 25] , was strongly associated with EBV-positive HL. Overall, our serological results corroborate our interview data, which suggests abnormal immunity in patients with EBV-positive HL.
The case-case design confers a number of advantages over the traditional case-control study design. The potential for selection bias was greatly reduced in our study, because the participation rate was high and enrollment was performed before the assessment of tumor EBV genome status, which left little chance of differential participation between EBV-positive and EBV-negative patients. Recall bias was also minimized, because patients were unlikely to know whether their tumors were EBV positive. This contrasts with a case-control comparison, in which individuals may choose to participate in a study and/or recall exposure information differently according to their disease status.
Because all blood specimens for our study were collected and tested after the diagnosis of HL, antibody levels may have changed after disease onset and may not reflect patients' immune profile before the development of HL. However, our findings are consistent with those from a recent companion prospective study of the US Armed Forces, in which an anti-EBNA-1:anti-EBNA-2 ratio р1.0 was significantly predictive of subsequent EBV-positive HL [64] . Taken together, these results suggest that an abnormal response to EBV infection, and perhaps impaired immune control of the virus, enables EBV to play an etiologic role in the development of HL in EBVpositive patients.
Although our results support the hypothesis that patients with EBV-positive HL have abnormal immunity, relative to patients with EBV-negative HL, a number of etiologic models for HL remain possible. First, EBV-positive and EBV-negative HL may share the same pathogenesis, with selective loss of the viral genome from EBV-negative HRS cells after viral transformation. In this "hit-and-run" model of HL pathogenesis, the viral genome could subsequently be eliminated from EBVnegative tumors by an active CTL response, or the virus could undergo deletion or rearrangement [65, 66] . However, that a small proportion of patients with HL have no serological evidence of prior infection with EBV and that all EBV-seronegative patients with known tumor status in our study were EBV negative indicate that EBV infection is not a prerequisite for HL. Also, efforts to detect defective or rearranged EBV genomes in HL have been unsuccessful [67] . These findings argue against the involvement of EBV in both EBV-positive and EBV-negative HL.
More likely, EBV-negative HL could be caused by a different, as-yet-unidentified infectious agent, or its development could be entirely independent of an infectious process. The association of overall HL with markers of late exposure to common childhood infections, including high maternal education, low sibship size, low housing density, and late birth order, strongly suggests that both EBV-positive and EBV-negative HL are associated with an infectious origin [5, 6, [68] [69] [70] . However, thorough searches for evidence of involvement of other lymphotropic herpesviruses in HL have thus far yielded negative results [71, 72] . Overall, our results suggest that diminished cellular immunity and an abnormal EBV response are associated with a greater risk of EBV-positive HL, whereas delayed childhood infection is a risk factor for HL in general. EBV clearly plays an etiologic role in EBV-positive HL; what infection or other factor plays a comparable role in EBV-negative HL remains to be determined. 
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